Petros Pharmaceuticals, Inc. Operating Lease, Expense
Petros Pharmaceuticals, Inc. (PTPI) reported Operating Lease, Expense of $97.62 thousand for the 9-month period ending 2023-09-30, per its 10-Q filed 2023-11-15.
Discontinued › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseExpense · last filed 2023-11-15
- Petros Pharmaceuticals, Inc. operating lease, expense for the quarter ending 2023-09-30 was $33.54K, a 12.94% increase year-over-year.
- Petros Pharmaceuticals, Inc. operating lease, expense for the quarter ending 2023-06-30 was $32.53K, a 12.89% increase year-over-year.
- Petros Pharmaceuticals, Inc. operating lease, expense for the quarter ending 2023-03-31 was $31.55K, a 12.83% increase year-over-year.
- Petros Pharmaceuticals, Inc. operating lease, expense for the quarter ending 2022-12-31 was $30.61K, a 12.78% increase year-over-year.
- Petros Pharmaceuticals, Inc. operating lease, expense for fiscal 2022 was $117.08K, a 12.61% increase from fiscal 2021.
- Petros Pharmaceuticals, Inc. operating lease, expense for fiscal 2021 was $103.98K, a 12.15% increase from fiscal 2020.
- Petros Pharmaceuticals, Inc. operating lease, expense for fiscal 2020 was $92.71K.
| Period end | Operating Lease, Expense 3 month | Operating Lease, Expense 6 month | Operating Lease, Expense 9 month | Operating Lease, Expense 12 month |
|---|---|---|---|---|
| 2023-09-30 | $33.54K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-15 | $66.07K derived: sum of 2 quarters · filed 2023-11-15 | $97.62K 10-Q · filed 2023-11-15 | $128.23K derived: sum of 4 quarters · filed 2023-11-15 |
| 2023-06-30 | $32.53K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | $64.08K 10-Q · filed 2023-08-14 | $94.69K derived: sum of 3 quarters · filed 2023-08-14 | $124.39K derived: sum of 4 quarters · filed 2023-11-15 |
| 2023-03-31 | $31.55K 10-Q · filed 2023-05-15 | $62.16K derived: sum of 2 quarters · filed 2023-05-15 | $91.86K derived: sum of 3 quarters · filed 2023-11-15 | $120.67K derived: sum of 4 quarters · filed 2023-11-15 |
| 2022-12-31 | $30.61K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | $60.31K derived: sum of 2 quarters · filed 2023-11-15 | $89.12K derived: sum of 3 quarters · filed 2023-11-15 | $117.08K 10-K · filed 2023-03-31 |
| 2022-09-30 | $29.70K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-15 | $58.52K derived: sum of 2 quarters · filed 2023-11-15 | $86.48K 10-Q · filed 2023-11-15 | $113.62K derived: sum of 4 quarters · filed 2023-11-15 |
| 2022-06-30 | $28.82K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | $56.78K 10-Q · filed 2023-08-14 | $83.92K derived: sum of 3 quarters · filed 2023-08-14 | $110.28K derived: sum of 4 quarters · filed 2023-08-14 |
| 2022-03-31 | $27.96K 10-Q · filed 2023-05-15 | $55.10K derived: sum of 2 quarters · filed 2023-05-15 | $81.46K derived: sum of 3 quarters · filed 2023-05-15 | $106.78K derived: sum of 4 quarters · filed 2023-05-15 |
| 2021-12-31 | $27.14K derived: 10-K 12 month − 10-Q/A 9 month · filed 2023-03-31 | $53.50K derived: sum of 2 quarters · filed 2023-03-31 | $78.82K derived: sum of 3 quarters · filed 2023-03-31 | $103.98K 10-K · filed 2023-03-31 |
| 2021-09-30 | $26.36K derived: 10-Q/A 9 month − 10-Q 6 month · filed 2022-11-15 | $51.68K derived: sum of 2 quarters · filed 2022-11-15 | $76.84K 10-Q/A · filed 2022-11-15 | $101.01K derived: sum of 4 quarters · filed 2022-11-15 |
| 2021-06-30 | $25.32K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-12 | $50.48K 10-Q · filed 2022-08-12 | $74.65K derived: sum of 3 quarters · filed 2022-08-12 | $98.15K derived: sum of 4 quarters · filed 2022-08-12 |
| 2021-03-31 | $25.16K 10-Q · filed 2022-05-16 | $49.33K derived: sum of 2 quarters · filed 2022-05-16 | $72.83K derived: sum of 3 quarters · filed 2022-05-16 | $95.67K derived: sum of 4 quarters · filed 2022-05-16 |
| 2020-12-31 | $24.17K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | $47.67K derived: sum of 2 quarters · filed 2022-03-31 | $70.51K derived: sum of 3 quarters · filed 2022-03-31 | $92.71K 10-K · filed 2022-03-31 |
| 2020-09-30 | $23.50K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-15 | $46.34K derived: sum of 2 quarters · filed 2021-11-15 | $68.54K 10-Q · filed 2021-11-15 | |
| 2020-06-30 | $22.84K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-16 | $45.04K 10-Q · filed 2021-08-16 | ||
| 2020-03-31 | $22.20K 10-Q · filed 2021-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| Sunshine Biopharma Inc. (SBFM) | $0.003B |